Jason Gotlib, Jean-Jacques Kiladjian, Alessandro Vannucchi, et al.

According to the study authors, the results of the study suggest that pemigatinib is a long-term treatment option for patients with MLN^FGFR1. This affects those who are not eligible for HSCT. Pemigatinib could also facilitate the transition to HSCT if the indication for treatment exists.

Francesca Palandri, Nicola Vianelli, David M Ross, et al.

Bomedemstat improves symptoms, is well tolerated, and reduces both platelet and white blood cell counts while maintaining hemoglobin levels. After six weeks, four out of five patients achieved complete remission of the peripheral blood count in the absence of disease progression.

Yi Zhang, Hu Zhou, Zhongxing Jiang, et al.

Jaktinib was well tolerated and safe in Chinese MF patients. With 100 mg BID, a significant reduction in the volume of the spleen and the burden of constitutional symptoms was achieved. There was also evidence of an improvement in red cell transfusion dependence.

Ronald Hoffman, Marina Kremyanskaya, Yelena Ginzburg, et al.

See abstract for more info.

Vikas Gupta, Abdulraheem Yacoub, Srdan Verstovsek, et al.

Fedratinb is generally well tolerated. Early GI prophylaxis can reduce the frequency and severity of gastrointestinal side effects. The thiamine level should be determined before the start of treatment and monitored regularly during treatment.

Yelena Ginzburg, Kamini Kirubamoorthy, Sinari Salleh, et al.

In order to quickly achieve a target hematocrit value below 45% in all PV patients without a phlebotomy, induction therapy with rusfertide administration twice a week has proven to be effective. It was successfully maintained with weekly rusfertide. Injections of rusfertide twice a week to rapidly lower the hematocrit was safe and well-tolerated.